Communiqués Insmed Incorporated

Actions

INSM

US4576693075

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 13/10/2026			Varia. 5j.	Varia. 1 janv.
96,79 ^USD	-1,80%		-6,78%	-44,39%

12/10	Les actions d’Insmed reculent après l’abaissement de recommandation de Wolfe Research	MT
12/10	Insmed Incorporated : Wolfe Research dégrade son opinion à neutre	ZM

Communiqués

05/10	Insmed Announces CFO Transition	PR
21/09	FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027	PR
16/09	Insmed Expands Community Impact During Fifth Annual Global Day of Good	PR
04/09	Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026	AQ
04/09	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
03/09	Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026	PR
26/08	Insmed to Present at September 2026 Investor Conferences	PR
24/08	BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease	PR
06/08	Insmed: Q2 Earnings Snapshot	AQ
06/08	Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update	PR
23/07	Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026	PR
16/07	Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension	PR
23/06	Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory	PR
05/06	Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	AQ
04/06	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
27/05	Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference	PR
07/05	Insmed: Q1 Earnings Snapshot	AQ
07/05	Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update	PR
06/05	Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis	PR
04/05	Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026	PR
30/04	Insmed to Present at May 2026 Investor Conferences	PR
23/04	Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026	PR
07/04	Insmed Provides Clinical Update on Phase 2b CEDAR Study	PR
23/03	Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease	PR
05/03	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR